期刊文献+

原发性肝癌患者术后甲胎蛋白异质体的变化及临床意义 被引量:2

原文传递
导出
摘要 目的:分析甲胎蛋白(AFP)及甲胎蛋白异质体L3(AFP-L3)在肝癌患者切除术前后的变化情况,探讨AFP-L3对肝癌患者术后的预后判断价值。方法:采集98例确诊为肝癌的患者于手术切除前、后的连贯血清(术前1份,术后连续留取),应用甲胎蛋白异质体微量离心柱分离并洗脱获得AFP-L3,再同时检测原始血清中AFP及AFP-L3含量,计算AFP-L3在总AFP中比率(AFP-L3%≥10%为阳性),对比手术切除前、后AFP含量及AFP-L3%的变化情况。结果:术后2个月AFP-L3阳性患者在未来28个月内的生存几率明显降低,AFP-L3阴性患者生存几率高;术后6个月AFP-L3阳性患者在未来24个月内的生存几率明显降低,AFP-L3阴性患者生存几率是100%;术后第l2个月AFP-L3阳性患者在未来18个月内的生存几率明显降低,AFP—L3阴性患者生存几率是100%。结论:AFP-L3对肝癌患者术后预后的判断具有重要的临床指导意义。
出处 《贵阳中医学院学报》 2014年第1期52-54,共3页 Journal of Guiyang University of Chinese Medicine
  • 相关文献

参考文献8

  • 1Parkin DM,Bray F,Ferlay PP. Global Cancer statistics 2002[J].{H}CA-A Cancer Journal for Clinicians,2005,(02):74-108.
  • 2黄彩云,韩素桂,张景华,王晓蕊,李世龙,周秀艳.ELISA法检测甲胎蛋白异质体用于肝癌诊断的探讨[J].标记免疫分析与临床,2012,19(3):147-149. 被引量:19
  • 3中国抗癌协会.新编常见恶性肿瘤诊治规范(原发性肝癌分册)[M]北京:北京医科大学与中国协和医科大学联合出版社,199922-23.
  • 4Evi N Debmyne,Joris R Ddlanghe. Diagnosmg and momtonng hepatocellular carcinoma with alpha-fetoprotein:new aspects and applications[J].{H}Clinica Chimica Acta,2008.19-26.
  • 5Yamashita F,TanakaM,Satomura S. Prognostic significance ofLens culinaris agglutinin a-reactive a-fetoprotein in small hepatocel-l ular carcinoma[J].J Gastroenterology,1996.996-1001.
  • 6Tada T,Kumada T,Toyoda H. Relationship between lens culi-naris agglutinin-reactive-fetoprotein and pathologic features of heptoeellular carcinoma[J].{H}Liver International,2005.1-6.
  • 7陈娇莲,钟伟润,陈德雄.介入治疗对肝癌患者AFP的影响[J].广东医学,2006,27(11):1719-1720. 被引量:4
  • 8Matsuda M,Asakawa M Amerimiya H. Lens eulinaris agglutinin-reactive fraction of AFP is a useful prognostic biommker for survival afer repeat hepatic resection for HCC[J].Gastroenteml Hepato1,2010.

二级参考文献12

  • 1青柳豊,韩少良.甲胎蛋白(AFP)L3组分[J].日本医学介绍,2005,26(2):49-50. 被引量:37
  • 2徐爱芳,王妙婵,眭东鸣,元幼红,陈刚,娄国强.新微量离心柱法检测甲胎蛋白异质体对肝癌诊断的研究[J].中华实验和临床病毒学杂志,2007,21(1):67-69. 被引量:19
  • 3陈灏珠.实用内科学[M].11版.北京:人民卫生出版社,2001:1826-1832.
  • 4WONG I H,LAU W Y,LEUNG T,et al.Quantitative comparis of afphafetoprotein and afbumin mRNA fevels in hepatocellular carcinoma/adenoma,nontumor fiver and blood:impflcations in cancer detection and monitoring[J].Cancer Lett,2000,156(2):141-149.
  • 5ADACHI E,METSUMATA T,NISHIZAKI T,et al.Effects of preoperative hepatic artery chemoembolization for hepatocellular carinoma.The relationship between postoperative course and tumor necrosis[J].Cancer,1993,72(9):3 593-3 598.
  • 6SCHONIGER HEKELE M,MUFFER C,KUTIFEK M,et al.Hepatocellular carcinoma in Central Europe:prognostic features and survival[J].Gut,2001,48(1):103-109.
  • 7Fujiyama S, Tanaka M, Maeda S, et al. Tumor markers in early di- agnosis , follow 2 up and management of patient s with hepatocellular carcinoma [ J]. Oncology, 2002,62 (Suppl 1 ): 57263.
  • 8Li D , Mallory T. AFP-L3 :a new generation of tumor marker for hep- atocellular carcinoma[ J ]. Clin Chim Acta,2001,313 (1-2) : 15-19.
  • 9FDA Class II Special Controls Cuidance Document : AFP- L3 ( % ) Im- munological Test Systems[ S]. Document Issued on October 4, 2005.
  • 10Leerapu A, Suravarapu S V , Bida J P, et al. The utility of Lensculi- naris agglutinin-reaelive alpha-fetoprotein in the diagnosis of hepato- cellular carcinoma: evaluation in a United States referral population [J]. Clin Gastroenterol Hepatol, 2007,5 : 394-402.

共引文献19

同被引文献17

引证文献2

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部